In vivo toxic and lethal cardiorespiratory effects of a synthetic quaternary ammonium salt derivative of haloperidol in mice

Abstract

Background: To investigate the toxicity of N-n-butyl haloperidol iodide (F2), a quaternary ammonium salt derivative of haloperidol, in mice for potential therapeutic purposes.

Methods: The acute median lethal dose (LD₅₀) of F2 was determined using the Bliss method following intravenous administration in mice. Routine surface electrocardiograms (ECGs) and arterial blood pressures (aBPs) were recorded under general anesthesia in untreated and pharmacologically vagotomized mice injected with F2. Sublethal doses of F2 were tested for their effects on aBP, heart rate, and biochemical parameters such as lactate dehydrogenase (LDH), blood urea nitrogen (BUN), and serum lactate levels. Histopathological changes in the heart, lungs, liver, and kidneys were evaluated after F2 administration.

Results: The acute LD₅₀ of F2 was determined to be 5.11 mg/kg. A 10 mg/kg dose of F2 caused severe hypotension, second-degree atrioventricular block, progressive prolongation of Pmurr intervals, and death due to cardiac asystole. Similar ECG and aBP changes were observed in atropine-pretreated mice, indicating that cholinergic effects do not play a major role in F2-induced toxicity. Sublethal doses of F2 (1.2 and 2.4 mg/kg) caused dose-dependent decreases in aBP and increases in heart rate. F2 induced significant, dose-dependent increases in LDH, BUN, and serum lactate levels. Histopathological analysis revealed acute lung lesions at 10 mg/kg, with no significant changes observed in the heart, liver, or kidneys.

Conclusion: Acute intravenous injection of F2 exhibits dose-dependent cardiopulmonary toxicity, characterized by severe hypotension, arrhythmias, and biochemical changes. These findings highlight the potential risks of F2 and the need for further evaluation of its safety profile for therapeutic use.

Keywords

acute toxicity / blood pressure / haloperidol / hemolysis / LD₅₀ / target prediction

References

[1] Lopez-Munoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull. 2009; 79: 130-141.

[2] Arena E, Dichiara M, Floresta G, et al. Novel Sigma-1 receptor antagonists: from opioids to small molecules: what is new? Future Med Chem. 2018; 10: 231-256.

[3] Jansen KL, Elliot M, Leslie RA. Sigma receptors in rat brain and testes show similar reductions in response to chronic haloperidol. Eur J Pharmacol. 1992; 214: 281-283.

[4] Shi GG, Xu SF. Effect of phencyclidine on coronary flow in isolated Guinea pig heart. Acta ACADEMIAE MEDICINAE Shanghai. 1994; 21: 93-96.

[5] Shi GG, Zheng JH, Chen SG. Haloperidol in the treatment of unstable angina pectoris: a report of 5 cases. Journal of Shantou University Medical College. 1997; 10: 33-34.

[6] Huang YP, Gao FF, Wang B, et al. N-n-butyl haloperidol iodide inhibits H₂O₂-induced Na+/Ca2+−exchanger activation via the Na+/H+ exchanger in rat ventricular myocytes. Drug Des Devel Ther. 2014; 8: 1257-1267.

[7] Gao FF, Shi GG, Zheng JH, Liu B. Protective effects of N-n-butyl haloperidol iodide on myocardial ischemia-reperfusion injury in rabbits. Chin J Physiol. 2004; 47: 61-66.

[8] Wang JZ, Cai CY, Zhang YM, et al. N-n-butyl haloperidol iodide protects against hypoxia/reoxygenation-induced cardiomyocyte injury by modulating protein kinase C activity. Biochem Pharmacol. 2010; 79: 1428-1436.

[9] Zhang Y, Chen G, Zhong S, et al. N-n-butyl haloperidol iodide ameliorates cardiomyocytes hypoxia/reoxygenation injury by extracellular calcium-dependent and -independent mechanisms. Oxidative Med Cell Longev. 2013; 2013: 912310.

[10] Zhang Y, Liao H, Zhong S, et al. Effect of N-n-butyl haloperidol iodide on ROS/JNK/Egr-1 signaling in H9c2 cells after hypoxia/reoxygenation. Sci Rep. 2015; 5: 11809.

[11] Lu S, Zhang Y, Zhong S, et al. N-n-butyl haloperidol iodide protects against hypoxia/reoxygenation injury in cardiac microvascular endothelial cells by regulating the ROS/MAPK/Egr-1 pathway. Front Pharmacol. 2016; 7: 520.

[12] Shen DF, Cheng H, Cai BZ, et al. N-n-butyl haloperidol iodide ameliorates liver fibrosis and hepatic stellate cell activation in mice. Acta Pharmacol Sin. 2022; 43: 133-145.

[13] Khan H, Ni Z, Feng H, et al. Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling. Phytomedicine. 2021; 91: 153706.

[14] Chen Y, Zheng J, Zheng F, et al. Design, synthesis, and pharmacological evaluation of haloperidol derivatives as novel potent calcium channel blockers with vasodilator activity. PLoS One. 2011; 6: e27673.

[15] Zheng JH, Shi GG, Pan Y, Li CC. Preparation of quaternary ammonium salt derivatives of haloperidol and their activities on coronary artery. Journal of China Pharmaceutical University. 2003; 34: 487-490.

[16] Li P, Zhao L. Developing early formulations: practice and perspective. Int J Pharm. 2007; 341: 1-19.

[17] Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020; 18: e3000410.

[18] Quelemes PV, de Araújo AR, Plácido A, et al. Quaternized cashew gum: an anti-staphylococcal and biocompatible cationic polymer for biotechnological applications. Carbohydr Polym. 2017; 157: 567-575.

[19] Sahariah P, Benediktssdóttir BE, Hjálmarsdóttir MÁ, et al. Impact of chain length on antibacterial activity and hemocompatibility of quaternary N-alkyl and N,N-Dialkyl chitosan derivatives. Biomacromolecules. 2015; 16: 1449-1460.

[20] Qi C, He J, Fu LH, et al. Tumor-specific activatable nanocarriers with gas-generation and signal amplification capabilities for tumor Theranostics. ACS Nano. 2021; 15: 1627-1639.

[21] Ilker MF, Nüsslein K, Tew GN, Coughlin EB. Tuning the hemolytic and antibacterial activities of amphiphilic polynorbornene derivatives. J Am Chem Soc. 2004; 126: 15870-15875.

[22] Sun R. A PARCTICAL combined method for computing the median lethal dose (LD50). Acta Pharm Sin. 1963; 10: 65-74.

[23] Grandic M, Sepcic K, Turk T, Juntes P, Frangez R. In vivo toxic and lethal cardiovascular effects of a synthetic polymeric 1,3-dodecylpyridinium salt in rodents. Toxicol Appl Pharmacol. 2011; 255: 86-93.

[24] Zuzek MC, Macek P, Sepcic K, Cestnik V, Frangez R. Toxic and lethal effects of ostreolysin, a cytolytic protein from edible oyster mushroom (Pleurotus ostreatus), in rodents. Toxicon. 2006; 48: 264-271.

[25] Sosa S, Del Favero G, De Bortoli M, et al. Palytoxin toxicity after acute oral administration in mice. Toxicol Lett. 2009; 191: 253-259.

[26] Association of Primate Veterinarians' humane endpoint guidelines for nonhuman primates in biomedical research. J Am Assoc Lab Anim Sci. 2020; 59: 6-8.

[27] Shaping the interaction landscape of bioactive molecules | Bioinformatics | Oxford Academic. n.d. Accessed February 7, 2024. https://academic.oup.com/bioinformatics/article/29/23/3073/249118

[28] Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019; 47(W1): W357-W364.

[29] Beach SR, Gross AF, Hartney KE, Taylor JB, Rundell JR. Intravenous haloperidol: a systematic review of side effects and recommendations for clinical use. Gen Hosp Psychiatry. 2020; 67: 42-50.

[30] P. A.S. Impulses in vagal afferent fibres from specific pulmonary deflation receptors the response of these receptors to phenyl diguanide, potato starch, 5-hydroxytryptamine and nicotine, and their role in respiratory and cardio-vascular reflexes. Q J Exp Physiol Cogn Med Sci. 1955; 40(2): 89-111.

[31] McCaffrey TV, Kern EB. Laryngeal regulation of airway resistance. II. Pulmonary receptor reflexes, the annals of otology. Ann Otol Rhinol Laryngol. 1980; 89: 462-466.

[32] Willette RN, Barcas PP, Krieger AJ, Sapru HN. Pulmonary resistance and compliance changes evoked by pulmonary opiate receptor stimulation. Eur J Pharmacol. 1983; 91: 181-188.

[33] Paintal AS, Damodaran VN, Guz A. Mechanism of excitation of type J receptors. Acta Neurobiol Exp. 1973; 33: 15-19.

[34] DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev. 2004; 23: 223-238.

[35] Benson BE, Spyker DA, Troutman WG, Watson WA, Bakhireva LN. Amlodipine toxicity in children less than 6 years of age: a dose-response analysis using national poison data system data. J Emerg Med. 2010; 39: 186-193.

[36] Zhan-Qin H, Gang-Gang S, Jin-Hong Z, Bing L. Effects of N-n-butyl haloperidol iodide on rat myocardial ischemia and reperfusion injury and L-type calcium current. Acta Pharmacol Sin. 2003; 24(8): 757-63.

[37] Huang Y, Gao F, Zhang Y, et al. N-n-butyl haloperidol iodide inhibits the augmented Na+/Ca2+ exchanger currents and L-type Ca2+ current induced by hypoxia/reoxygenation or H₂O₂ in cardiomyocytes. Biochem Biophys Res Commun. 2012; 421: 86-90.

[38] Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of Pharmaceuticals in Humans and in animals. Regul Toxicol Pharmacol. 2000; 32: 56-67.

[39] Evans G, ed. Animal Clinical Chemistry: A Practical Handbook for Toxicologists and Biomedical Researchers. 2nd ed. CRC Press; 2009.

[40] Janotka M, Ostadal P. Biochemical markers for clinical monitoring of tissue perfusion. Mol Cell Biochem. 2021; 476: 1313-1326.

[41] James JH, Fang CH, Schrantz SJ, Hasselgren PO, Paul RJ, Fischer JE. Linkage of aerobic glycolysis to sodium-potassium transport in rat skeletal muscle Implications for increased muscle lactate production in sepsis. J Clin Invest. 1996; 98: 2388-2397.

[42] Levy B, Desebbe O, Montemont C, Gibot S. Increased aerobic glycolysis through beta2 stimulation is a common mechanism involved in lactate formation during shock states. Shock. 2008; 30: 417-421.

[43] Pinsky MR, Cecconi M, Chew MS, et al. Effective hemodynamic monitoring. Crit Care. 2022; 26: 294.

[44] Suetrong B, Walley KR. Lactic acidosis in sepsis: It's not all anaerobic: implications for diagnosis and management. Chest. 2016; 149: 252-261.

[45] Bürger C, Fischer DR, Cordenunzzi DA, et al. Acute and subacute toxicity of the hydroalcoholic extract from Wedelia paludosa (Acmela brasiliensis) (Asteraceae) in mice. J Pharm Pharm Sci. 2005; 8: 370-373.

[46] Wang TC, Su YP, Hsu TY, Yang CC, Lin CC. 28-day oral toxicity study of the aqueous extract from spider brake (Pteris multifida Poiret) in rats. Food Chem Toxicol. 2007; 45: 1757-1763.

[47] Witthawaskul P, Panthong A, Kanjanapothi D, Taesothikul T, Lertprasertsuke N. Acute and subacute toxicities of the saponin mixture isolated from Schefflera leucantha Viguier. J Ethnopharmacol. 2003; 89: 115-121.

[48] Tennekoon KH, Jeevathayaparan S, Kurukulasooriya AP, Karunanayake EH. Possible hepatotoxicity of Nigella sativa seeds and Dregea volubilis leaves. J Ethnopharmacol. 1991; 31: 283-289.

[49] Hassan SW, Ladan MJ, Dogondaji RA, et al. Phytochemical and toxicological studies of aqueous leaves extracts of Erythrophleum africanum. Pak J Biol Sci. 2007; 10: 3815-3821.

[50] Rhiouani H, El-Hilaly J, Israili ZH, Lyoussi B. Acute and sub-chronic toxicity of an aqueous extract of the leaves of Herniaria glabra in rodents. J Ethnopharmacol. 2008; 118: 378-386.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.